[A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency]. 1997

G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
Laboratoire de biologie hormonale, hôpital St-Louis, Parix.

The syndrome of apparent mineralocorticoid excess is a recessively inherited form of low renin hypertension. The syndrome is characterised by sodium retention and hypervolemia despite low plasma renin activity and aldosterone levels. Patients with this syndrome have mutations in the 11HSD2 gene which encodes the enzyme which normally converts cortisol in the renal tubule to its inactive form, cortisone. The unconverted cortisol is thus able to bind and activate the mineralocorticoid receptor, displacing its usual ligand, aldosterone, causing the apparent mineralocorticoid excess. We have studied a patient with severe hypertension, low renin and aldosterone, and a chronic hypokalemic alkalosis at age 4. The analysis of cortisone, cortisol and their metabolites showed the specific pattern of the apparent mineralocorticoid excess. In serum and urine, there was a dramatic decrease of cortisone and its metabolite, while cortisol and its metabolites were non affected.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008901 Mineralocorticoids A group of CORTICOSTEROIDS primarily associated with water and electrolyte balance. This is accomplished through the effect on ION TRANSPORT in renal tubules, resulting in retention of sodium and loss of potassium. Mineralocorticoid secretion is itself regulated by PLASMA VOLUME, serum potassium, and ANGIOTENSIN II. Mineralocorticoid,Mineralocorticoid Effect,Mineralocorticoid Effects,Effect, Mineralocorticoid,Effects, Mineralocorticoid
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003348 Cortisone A naturally occurring glucocorticoid that has been used in replacement therapy for ADRENAL INSUFFICIENCY and as an anti-inflammatory agent. Cortisone itself is inactive; it is converted in the liver to the active metabolite HYDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726) 17-Hydroxy-3,11,20-trioxopregn-4-en-21-yl acetate,Adreson,Cortisone Acetate,Cortone Acetate
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006913 Hydroxysteroid Dehydrogenases Enzymes of the oxidoreductase class that catalyze the dehydrogenation of hydroxysteroids. (From Enzyme Nomenclature, 1992) EC 1.1.-. Hydroxysteroid Dehydrogenase,Dehydrogenase, Hydroxysteroid,Dehydrogenases, Hydroxysteroid

Related Publications

G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
August 1995, Clinical endocrinology,
G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
May 2006, Nihon rinsho. Japanese journal of clinical medicine,
G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
February 1997, Endocrine reviews,
G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
June 2003, The Journal of clinical endocrinology and metabolism,
G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
March 2017, Journal of hypertension,
G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
December 1997, The Journal of clinical endocrinology and metabolism,
G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
March 1996, Clinical endocrinology,
G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
August 1995, Clinical endocrinology,
G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
December 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
G Morineau, and L Pascoe, and J M Marc, and A Caillette, and Z Krozowski, and P Corvol, and J Fiet
January 1997, Pediatric research,
Copied contents to your clipboard!